The Incidence, Epidemiology, Clinical Characteristic, Prognostic Factors, Therapy and Outcome of Non-Hodgkin Lymphoma Patients in the Czech Republic. NiHiL- Longitudinal Observational Study of Czech Lymphoma Study Group (CLSG)

Status: Recruiting
Study Type: Observational
SUMMARY

The Czech National Lymphoma Registry (NiHiL) was founded to monitor epidemiologic data and improve the diagnostic evaluation and quality of treatment of patients with non-Hodgkin´s lymphoma (NHL). The patients are registered into the registry in anonymized form. For each patient are available: registration form, diagnostic form, treatment form, follow- up form, and other malignancy form. Data quality in the NiHiL has been checked by audits. The data is analyzed according to NHL subtypes with endpoints: lymphoma distribution, epidemiological data, prognostic characteristic, treatment characteristics, response rate, relapse rate, mortality, PFS, OS, DFS, Lymphoma specific survival, longterm toxicity.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• lymphoma diagnosis

• treated in the Czech Republic

• signed informed consent

Contact Information
Primary
Marek Trneny, prof. MD
trneny@cesnet.cz
+420224962061
Backup
David Belada, MD
david.belada@seznam.cz
+420495 832 866
Time Frame
Start Date: 1999-01-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 20000
Treatments
All NHL subtypes
no interventions
DLBCL
only patients with diffuse large B-cell lymphoma
FL
only patients with follicular lymphoma
MCL
only patients with mantle cell lymphoma
SLL/CLL
only patients with small lymphocytic lymphoma / chronic lymphocytic leukemia
MZL
only patients with marginal zone lymphoma
other B-cell lymphomas
only patients with B-lymphomas not described above
T-cell lymphomas
only patients with all types of T-cell lymphoma
Related Therapeutic Areas
Sponsors
Leads: Czech Lymphoma Study Group

This content was sourced from clinicaltrials.gov